Hoth Therapeutics, Inc. (HOTH)

Market Cap	5.71M
Revenue (ttm)	n/a
Net Income (ttm)	-7.51M
Shares Out	6.90M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,978,167
Open	0.950
Previous Close	0.818
Day's Range	0.818 - 1.020
52-Week Range	0.580 - 1.730
Beta	0.84
Analysts	Strong Buy
Price Target	4.75 (+474.64%)
Earnings Date	Nov 12, 2024

About HOTH

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or ot...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 15, 2019
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: HOTH
• Website: https://hoththerapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for HOTH stock is "Strong Buy." The 12-month stock price forecast is $4.75, which is an increase of 474.64% from the latest price.

Price Target

$4.75

(474.64% upside)

Analyst Consensus: Strong Buy